Mucopolysaccharidosis Type Vi – 2018-2028 –

Epidemiology Series: Mucopolysaccharidosis Type Vi Forecast In 30 Major
Markets 2018-2028”
report has been added to’s

This report provides the current prevalent population for MPS VI across
30 Major Markets split by gender and 5-year age cohort. In addition to
the current prevalence, the report provides an overview of the risk
factors, diagnosis and prognosis of the disease, along with specific
variations by geography and ethnicity.

Providing a value-added level of insight from our analysis team, MPS VI
patients grouped by disease severity and comorbidities have been
quantified and presented alongside the overall prevalence figures. These
sub-populations within the main disease are also included at a country
level across the 10-year forecast snapshot.

Markets Featured:

  • USA
  • Canada
  • France
  • Germany
  • Italy
  • Spain
  • UK
  • Poland
  • Netherlands
  • Belgium
  • Norway
  • Sweden
  • Denmark
  • Austria
  • Switzerland
  • Portugal
  • Czech Republic
  • Lithuania
  • Estonia
  • Russia
  • Turkey
  • Saudi Arabia
  • Japan
  • China
  • South Korea
  • India
  • Australia
  • Brazil
  • Mexico
  • Argentina

Main symptoms and co-morbidities of MPS VI include:

  • Cardiac valvular dysfunction
  • Heart failure
  • Recurrent airway (pneumonia, sinusitis) and ear (otitis media)
  • Respiratory failure
  • Obstructive sleep apnoea
  • Pulmonary hypertension
  • Joint disease
  • Cervical spine compression
  • Hydrocephalus
  • Glaucoma
  • Deafness
  • Umbilical and inguinal hernia

Reasons to buy:

  • Ability to quantify patient populations in global MPS VI market to
    target the development of future products, pricing strategies and
    launch plans.
  • Further insight into the prevalence of the subdivided types of MPS VI
    and identification of patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study
    sizing and realistic patient recruitment for various countries.
  • Better understanding of the impact of specific co-morbid conditions on
    the prevalent population of MPS VI patients.
  • Identification of MPS VI patient sub-populations that require
  • Better understanding of the specific markets that have the largest
    number of MPS VI patients.

Key Topics Covered:

  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key Comorbid Conditions/Features Associated with the Disease
  • Methodology for Quantification of Patient Numbers
  • Top-Line Prevalence for Mucopolysaccharidosis Type Vi
  • Features of Mucopolysaccharidosis Type Vi Patients
  • Comorbidities of Mucopolysaccharidosis Type Vi Patients
  • Online Epidemiology Databases
  • Online Pharmaceutical Pricing Database

For more information about this report visit

Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Topics: Immune
Disorders Drugs
, Endocrine
and Metabolic Disorders Drugs